Treatment of MM: Upcoming Novel Therapies
1Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd, Building C, Room 4004, Atlanta, GA, 30322, USA. sloni01@emory.edu.
Abstract:
Treatment for myeloma has dramatically changed over the past decade, as has overall survival, due in large part to the development of new targeted agents. While proteasome inhibitors and immunomodulatory agents have contributed to improved outcomes, additional new options remain an unmet medical need. Classes of emerging agents include those targeting epigenetics, such as histone deacetylase inhibitors, monoclonal antibodies, and other emerging targets, such as kinesin spindle protein (KSP) inhibitors, cyclin dependent kinase (CDK) inhibitors, and nuclear protein export inhibitors. Future treatment approaches will need to identify how and when to incorporate these treatment options to optimally treat patients with relapsed or refractory myeloma.
Insights
New targeted agents have improved survival for multiple myeloma (MM). Emerging therapies like epigenetic modifiers and kinesin spindle protein (KSP) inhibitors offer new hope for relapsed or refractory MM patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Multiple myeloma (MM) treatment has advanced significantly in the last decade.
- Improved overall survival is largely attributed to novel targeted therapies.
- Despite progress, unmet needs persist for patients with relapsed or refractory MM.
Purpose of the Study:
- To review the evolving landscape of multiple myeloma therapeutics.
- To highlight emerging drug classes and their potential targets.
- To discuss future treatment strategies for relapsed or refractory MM.
Main Methods:
- Literature review of recent advancements in MM treatment.
- Categorization of novel therapeutic agents by mechanism of action.
- Analysis of emerging targets including epigenetics, KSP, CDK, and nuclear export.
Main Results:
- Proteasome inhibitors and immunomodulatory drugs have enhanced patient outcomes.
- Emerging agents include histone deacetylase inhibitors, monoclonal antibodies, KSP inhibitors, CDK inhibitors, and nuclear protein export inhibitors.
- These novel agents represent promising options for difficult-to-treat MM.
Conclusions:
- The therapeutic arsenal for multiple myeloma continues to expand.
- Optimal integration of novel agents into treatment paradigms is crucial.
- Future research should focus on sequencing and combination strategies for refractory MM.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies